Mizuho's Jared Holz joins the 'Fast Money' team to discuss the potential impact of expiring patents within the biotech and ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

The biotech giant that soared during Operation Warp Speed now faces regulatory hurdles, political scepticism, and dwindling ...

Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals ...

Seven pharmaceutical giants with a presence in New Jersey have announced billions in expansions. The timing is no surprise, health care analysts say.

"The stock shakes off almost every fundamental issue/set-back and still manages to outperform most peers," wrote Mizuho healthcare equity strategist Jared Holz in a note to clients on Nov. 10 ...

Mizuho Americas healthcare equity strategist Jared Holz joins Market Domination with Josh Lipton and Julie Hyman to explain why he's telling clients to stay away from the stock for now.

The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics ...

On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC’s ‘Power Lunch’ to discuss investing in biotech and the oversaturation in the sector. He said that looking at ...

Is the Biotech Sector Oversaturated? On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC’s ‘Power Lunch’ to discuss investing in biotech and the oversaturation in ...

What’s Going on in the Pharma Sector? On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on ‘Squawk Box’ to discuss the potential challenges and opportunities the ...

Kennedy Jr. as the new Health and Human Services (HHS) secretary, according to Mizuho's healthcare expert Jared Holz, largely driven by retail investor interest. "Our sense, is that the RFK-led ...